PYY(3-36)–DPP-IV Compositions for Lower-Dose Oral Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for obesity and metabolic disorders, such as DPP-IV inhibitors, have variable efficacy and significant side effects, and there is a lack of effective, long-term, non-invasive therapies.
Innovation Solution
Compositions comprising PYY(3-36) and a DPP-IV inhibitor are developed for local oral delivery, aiming to synergistically reduce food intake and enhance satiety, with PYY(3-36) doses no greater than 250 ng and DPP-IV inhibitors administered in suitable doses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If DPP-IV inhibitors are used to treat metabolic disorders, then glycemic control is improved, but body weight loss effect is insufficient and side effects increase
Solution Approach 1:
The patent combines PYY(3-36) peptide with DPP-IV inhibitor in a single composition for synergistic effect. PYY(3-36) provides weight loss and satiety effects while DPP-IV inhibitor provides glycemic control, and their combination enhances overall metabolic treatment efficacy while allowing lower doses of each component, thereby reducing side effects.
Solution Approach 2:
The invention creates a composite therapeutic formulation containing both PYY(3-36) peptide and DPP-IV inhibitor. This composite approach leverages the complementary mechanisms of action of both agents to achieve multiple therapeutic outcomes (glycemic control, weight loss, satiety) simultaneously with improved safety profile.
2Productivity
If high doses of PYY(3-36) are administered to reduce food intake, then satiety effect is improved, but systemic side effects increase
Solution Approach 1:
By combining PYY(3-36) with DPP-IV inhibitor, the patent achieves enhanced satiety effect through synergistic interaction. The DPP-IV inhibitor prevents degradation of endogenous GLP-1 and enhances the satiety signal, allowing lower doses of PYY(3-36) to achieve the same therapeutic effect, thereby reducing systemic side effects.
Solution Approach 2:
The DPP-IV inhibitor acts as a mediator that enhances and prolongs the activity of both exogenous PYY(3-36) and endogenous GLP-1. By inhibiting DPP-IV enzyme, it prevents rapid breakdown of these satiety-inducing peptides, thereby amplifying their effect at lower doses and reducing the need for high PYY(3-36) administration.
3Productivity
If current obesity treatments are used, then weight loss is achieved, but efficacy is highly variable and long-term effectiveness is insufficient
Solution Approach 1:
The patent combines two mechanisms (PYY(3-36) acting on Y2 receptors and DPP-IV inhibition) that work through different pathways to produce weight loss. This dual mechanism approach provides more consistent and reliable efficacy by targeting multiple aspects of appetite regulation and metabolism, reducing the variability seen with single-agent therapies.
Solution Approach 2:
The composite formulation of PYY(3-36) and DPP-IV inhibitor creates a synergistic therapeutic system that addresses multiple metabolic parameters simultaneously. This composite approach provides more reliable and consistent weight loss outcomes by leveraging complementary mechanisms of action.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of PYY(3-36) and DPP-IV inhibitors effectively reduces food intake by 20% and body weight by 5%, while minimizing systemic side effects, offering a more consistent and safer treatment approach for obesity and metabolic disorders.
Implementation Method 1
PYY(3-36) secretion is related to caloric intake, and it induces satiation by acting on Y2 receptors in the arcuate nucleus of the hypothalamus
Implementation Method 2
PYY(3-36) and Y2 receptors are expressed in the taste cells in the circumvallate papilla of the tongue
Implementation Method 3
GLP-1 and GLP-1 agonists reduce fasting and postprandial glucose levels via increased insulin secretion from the pancreas
Implementation Method 4
GLP-1 receptor agonists also retard gastric emptying and decrease food intake by 19%
Implementation Method 5
DPP-IV inhibitors were developed to increase the circulating levels of endogenous GLP-1, and to treat hyperglycemia
Implementation Method 6
Its amino acid sequence shares 53% identity with GLP-1, but its half-life is prolonged due to its resistance to rapid breakdown by dipeptidyl peptidase 4 (DPP-IV)
Data Source
AI summary
Compositions comprising satiety peptides (e.g., PYY, PYY(3-36), GLP-1, oxyntomodulin, and cholecystokinin) and DPP-IV inhibitors and methods of treating metabolic diseases with such compositions are provided.